CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Assessing antibody responses, neutralizing capacity and memory B-cell functionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1330 Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) Wiki 1.00
drug3121 Wharton's jelly derived Mesenchymal stem cells. Wiki 1.00

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D013577 Syndrome NIH 0.10
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.09
D012128 Respiratory Distress Syndrome, Adult NIH 0.08

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?

The objectives of this study are (1) to determine the ex vivo neutralizing capacity and the longevity of SARS-CoV-2-specific Ab responses and (2) to measure the memory B-cell responses in a cohort of health care workers (HCW) recovering from severe, mild or asymptomatic infection. By focusing on HCW, a population that is at risk for re-infection during a second epidemic wave, the correlation between nAb levels and protection is investigated.

NCT04469634 SARS-CoV2 COVID-19 Diagnostic Test: Assessing antibody responses, neutralizing capacity and memory B-cell function

Primary Outcomes

Measure: Antibody levels over time

Time: 12 months

Measure: Antibody neutralizing capacity

Time: 12 months

Measure: Memory B-cell function

Time: 12 months

Measure: Antibody-dependent enhancement

Time: 12 months

Secondary Outcomes

Measure: Re-infection with SARS-CoV2

Time: 12 months

No related HPO nodes (Using clinical trials)